Search Results

Deamidated Gliadin Peptide (DGP) Antibody, IgA Ordering Recommendation Acceptable single screening test for celiac disease. IgA testing recommended to identify IgA deficiency. Use IgA test in individuals who are IgA competent. May be useful in diagnosing children <2 years who test negative for tTG and EMA antibodies. May aid in monitoring adherence to gluten-free diet. Celiac Disease Reflexive Cascade (2008114 ) or Tissue Transglutaminase (tTG) Antibody, IgA (0097709 ) is the preferred test for screening patients with suspected celiac disease. Mnemonic Methodology Semi-Quantitative Enzyme-Linked Immunosorbent Assay Performed Mon-Sat Reported 1-2 Days New York DOH Approval Status This test is New York DOH approved. Specimen Required Patient Preparation: Collect: Serum separator tube (SST). Specimen Preparation: Separate serum from cells ASAP or within 2 hours of collection. Transport 0.5 mL serum. (Min: 0.3 mL) Storage/Transport Temperature: Refrigerated Unacceptable Conditions: Plasma or other body fluids. Contaminated, hemolyzed, grossly icteric, or grossly lipemic specimens. Remarks: Plasma. Hemolyzed or severely lipemic specimens. Stability: After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year Reference Interval 19 Units or less 20-30 Units Negative Weak Positive 31 Units or greater Positive Interpretive Data Note Human recombinant tTG antigen is utilized in this assay CPT Code 86258 Components Component Chart Name ​ Deamidated Gliadin Peptide (DGP) Ab, IgA Component Test Code 0051357 LOINC 63453-5 Aliases Celiac Disease Antibodies Coeliac Disease Antib odies Deamidated Gliadin Antibodies (DGP) Deaminated Gliadin Peptide Antibodies ​ DGP DGP Ab DGP IgA ​

Beta-2 Glycoprotein 1 Antibodies, IgG and IgM Ordering Recommendation Acceptable initial test when antiphospholipid syndrome (APS) is strongly suspected. Order with Lupus Anticoagulant Reflexive Panel (0030181 ) and Cardiolipin Antibodies, IgG and IgM (0099344 ). May also be useful in estimating risk of thrombosis and/or pregnancy-related morbidity in patients with systemic lupus erythematosus (SLE). Mnemonic B2GPI PAN Performed Mon-Sat Methodology Semi-Quantitative Enzyme-Linked Immunosorbent Assay Reported 1-2 days New York DOH Approval Status This test is New York DOH approved. Specimen Required Patient Preparation: Collect: Serum separator tube. Specimen Preparation: Separate serum from cells ASAP or within 2 hours of collection. (Min: 0.3 mL) Storage/Transport Temperature: Refrigerated. Unacceptable Conditions: Plasma or other body fluids. Contaminated, hemolyzed, grossly icteric, or severely lipemic specimens. Remarks: Stability: After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year (avoid repeated freeze/thaw cycles) Reference Interval Reference Interval Components <=20 SGU B2Glycoprotein 1, IgG Antibody <=20 SMU B2Glycoprotein 1, IgM Antibody Interpretive Data The persistent presence of IgG and/or IgM beta 2 glycoprotein I (B2GPI) antibodies is a laboratory criterion for the diagnosis of antiphospholipid syndrome (APS). Persistence is defined as moderate or high levels of IgG and/or IgM B2GPI antibodies detected in two or more specimens drawn at least 12 weeks apart (J Throm Haemost. 2006;4:295-306). B2GPI results greater than 20 SGU (IgG) and/or SMU (IgM) are considered positive based on the cutoff values established for this test. International reference materials and consensus units for anti-B2GPI antibodies have not been established (Clin Chim Acta. 2012;413(1-2):358-60; Arthritis Rheum. 2012;64(1):1-10.); results can be variable between different commercial immunoassays and cannot be compared. Strong clinical correlation is recommended for a diagnosis of APS. Low positive IgG and IgM B2GPI antibody levels should be interpreted in light of APS-specific clinical manifestations and/or other criteria phospholipid antibody tests. Compliance Category: FDA Note MPL = IgM phospholipid units CPT Code 86146 x2 Components Component Chart Name B2Glycoprotein 1, IgG Antibody Component Test Code 0050322 LOINC 44448-9 0050323 B2Glycoprotein 1, IgM Antibody 44449-7 Aliases Anti-B2-Glycoprotein 1 Anti-B2-Glycoprotein I Anti-B2-GP 1 Anti-B2-GP1 Anti-B2-GPI Anti-beta-2 glycoprotein 1 Anti-beta-2 glycoprotein I Apolipoprotein H Apolipoprotein H, APOH B2 Glycoprotein 1 antibodies B2GP Antibodies B2GP1 B2GPI IgG, IgM BECKY Beta 2 GP1 Ab IgG Beta 2 GP1 Ab IgM Beta 2GP1 Ab Beta 2Glycoprotein 1

Cardiolipin Antibody, IgM Ordering Recommendation Acceptable initial test when antiphospholipid syndrome (APS) is highly suspected. Order with Lupus Anticoagulant Reflexive Panel (0030181 ) and Beta-2 Glycoprotein 1 Antibodies, IgG and IgM (0050321 ). Cardiolipin Antibodies, IgG and IgM (0099344 ) is preferred. Mnemonic AC-IGM Performed Mon-Sat Methodology Semi-Quantitative Enzyme-Linked Immunosorbent Assay Reported 1-2 days New York DOH Approval Status This test is New York DOH approved. Specimen Required Patient Preparation: Collect: Serum separator tube. Specimen Preparation: Separate serum from cells ASAP or within 2 hours of collection. Transfer 1 mL serum to a Standard Transport Tube. (Min: 0.3 mL) Storage/Transport Temperature: Refrigerated. Unacceptable Conditions: Plasma or other body fluids. Contaminated, heat-inactivated, hemolyzed, or lipemic specimens. Remarks: Stability: After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year Reference Interval <=12 MPL Negative 13-19 MPL Indeterminate 20-80 MPL Low to Moderately Positive 81 MPL or above High Positive Interpretive Data The persistent presence of IgG and/or IgM cardiolipin (CL) antibodies in moderate or high levels (greater than 40 GPL and/or greater than 40 MPL units) is a laboratory criterion for the diagnosis of antiphospholipid syndrome (APS). Persistence is defined as moderate or high levels of IgG and/or IgM CL antibodies detected in two or more specimens drawn at least 12 weeks apart (J Throm Haemost. 2006;4:295-306). Lower positive levels of IgG and/or IgM CL antibodies (above cutoff but less than 40 GPL and/or less than 40 MPL units) may occur in patients with the clinical symptoms of APS; therefore, the actual significance of these levels is undefined. Results should not be used alone for diagnosis and must be interpreted in light of APS-specific clinical manifestations and/or other criteria phospholipid antibody tests. Compliance Category: FDA Note MPL = IgM phospholipid units CPT Code 86147 Components Component Chart Name Cardiolipin Antibody IgM Component Test Code 0050902 LOINC 3182-3 Aliases ACA aCL aCL Antibody aCL IgG Anti-Cardiolipin Anticardiolipin Anticardiolipin Antibodies Cardiolip